MCR Acquires Cloud-Based Hotel Management Platform Optii
7.12.2021 17:00:00 EET | Business Wire | Press release
MCR, the 4th-largest hotel owner-operator in the United States and one of Fast Company’s 10 Most Innovative Travel Companies of 2020, has acquired Optii, the only predictive, cloud-based technology for improved hotel operations.
Optii will continue to be a standalone company with its existing management team of CEO Katherine Grass, Founder and CSO Soenke Weiss and CRO Deborah Pevenstein.
MCR’s portfolio of 140 branded and independent hotels will be arms-length customers of Optii, which will continue to offer its product to forward-thinking hotel companies. No data will be shared with MCR. MCR will mobilize its 4,000 hotel team members — who will utilize Optii for 20,000 guestrooms per day — to push for innovative product enhancements.
Stayntouch property management system software, another standalone company owned by MCR, will integrate with Optii.
A data-driven platform powered by artificial intelligence, Optii has revolutionized housekeeping technology, optimizing labor and cleaning sequences for faster turnaround times and reduced costs. With its Service and Chat products, Optii streamlines internal communication, allowing managers to auto-assign and track jobs and guest requests in real time, eliminating calls by 95%. The user-friendly mobile and tablet interface can be accessed anywhere, whether on or off property.
Used by hotels to clean more than 10 million guestrooms globally, Optii has experienced stratospheric growth in the past year as hoteliers seek to increase housekeeping productivity while committing to Covid-19 protocols and facing labor shortages.
Fully configurable, the platform connects to many property management systems and is a best-in-class solution for hotels of all sizes, from 50-room boutique properties to 3,000-room casinos. Unlike any other hotel technology, remote onboarding is led by the experts — former executive housekeepers. The software’s artificial intelligence gets smarter over time — around week four, the technology peaks in providing operational efficiencies.
Optii has an aggressive expansion strategy that includes the imminent introduction of a Preventative Maintenance product.
Katherine Grass, CEO of Optii, says, “We are honored to have been selected by MCR to join their portfolio of companies. This acquisition will significantly boost our ability to provide hotels around the world with the technology they need to succeed in today’s operating environment. More and more hotels are realizing that investing in the right technology at this unique time can be a key lever for success. This is a huge growth opportunity for our company to continue momentum in the United States and Europe as well as to further develop our leadership position in Asia.”
Adds Tyler Morse, Chairman and CEO of MCR, “Innovation is a core value of MCR and the acquisition of Optii forwards our mission. At our 140 hotels, we have used every housekeeping technology on the market — and Optii is simply the best. MCR’s investment in Optii will expand its reach globally and provide the company with the resources to continue introducing cutting-edge technology to the hotel industry.”
About Optii Solutions
Optii, headquartered in Austin, Texas, and with offices in New York, London and Brisbane, is a hotel operations solution that leverages smarter technologies such as artificial intelligence, analytics, messaging and mobility to improve the efficiency and effectiveness of hotel operations teams. Optii operates in real time and allows hotels to streamline operations, reduce costs and enhance the guest experience in proven and tangible ways, without requiring capital expenditure and complex integrations. Optii is used by hotels around the world, including the Venetian Macau, part of Las Vegas Sands, La Cantera Resort & Spa and The Don Cesar in the United States, Okada Manilla Resort & Casino, Doma Hotels, Marriott, IHG and more. For further information about Optii, please visit optiisolutions.com.
About MCR
- 4th-largest hotel owner-operator in the United States
- $4.0 billion portfolio of 140 premium-branded hotels
- MCR operates 8 Marriott brands, 6 Hilton brands and a number of unflagged independent hotels
- 20,000 guestrooms across 34 states and 84 cities
- Founded in 2006
- Offices in New York City, Dallas, Chicago and Richmond, Virginia
- 4,000 team members across the country
- Three-time recipient of the Marriott Partnership Circle Award , the highest honor Marriott presents to its owner and franchise partners
- Recipient of the Hilton Legacy Award for Top Performer
- For the TWA Hotel at New York’s JFK Airport, MCR won the Development of the Year (Full Service) Award at The Americas Lodging Investment Summit (ALIS) , the Urban Land Institute New York Excellence in Hotel Development Award and the American Institute of Architects national Architecture Award, the highest honor given by the AIA
- Named one of Fast Company’s 10 Most Innovative Travel Companies of 2020
- For more information, please visit mcrhotels.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005258/en/
Contact information
Ellie Box: ebox@fireoth.com, +44 7974 791119
Sarah Mulder: smulder@fireoth.com, +44 7720401466
info@mcrhotels.com
(203) 682-8277
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
